Cited by 362Nutrition and Health in AgingBody Composition Measurement TechniquesSarcoma Diagnosis and Treatment

Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy

Open access
Baracos, V.E., Arribas, L.·2018·Annals of Oncology

Abstract

Body composition, defined as the proportions and distribution of lean and fat tissues in the human body, is an emergent theme in clinical oncology. Severe muscle depletion (sarcopenia) is most easily overlooked in obese patients; the advent of secondary analysis of oncologic images provides a precise and specific assessment of sarcopenia. Here, we review the definitions, prevalence and clinical implications of sarcopenic obesity (SO) in medical and surgical oncology. Reported prevalence of SO varies due to the heterogeneity in the definitions and the variability in the cut points used to define low muscle mass and high fat mass. Prevalence of SO in advanced solid tumor patient populations average 9% (range 2.3%-14.6%) overall, and one in four (24.7%, range 5.9%-39.2%) patients with body mass index ≥ 30 kg/m2 are sarcopenic. SO is independently associated with higher mortality and higher rate of complications in systemic and surgical cancer treatment, across multiple cancer sites and treatment plans. These associations remain unexplained, however, it has been hypothesized that patients with sarcopenia are generally unfit and unable to tolerate stress. Another proposed mechanism relates to increased exposure to antineoplastic therapy, i.e. a large fat mass would be expected to inflate drug dose in BSA-based treatments, causing an increased rate of dose-limiting toxicity. Pharmacokinetic data are needed to confirm or refute this hypothesis. Old age, deconditioning, cancer progression, acute or chronic nonmalignant disease and drug side-effects are suggested causes of muscle loss, and it is unknown the degree to which this can be reversed. Sarcopenia can be readily detected before start of cancer treatment, however, clinical management protocols for SO patients require development. Studies of cancer treatment dose-modulation are in progress.

Integrity signals

Registry

Crossref · 10.1093/annonc/mdx810

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Adverse clinical cancer outcomes are reported to be relevant to sarcopenic obesity, especially with respect to dose-limiting toxicity, surgical complications, physical disability, and shorter survival.

    “Moreover, adverse clinical cancer outcomes reported to be relevant to SO, especially with respect to dose-limiting toxicity, surgical complications, physical disability, and shorter survival (59–61).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Baracos, V. E., & Arribas, L.
Affiliations
  • University of Alberta (CA)
  • Institut d'Investigació Biomédica de Bellvitge (ES)
Corresponding author
Baracos, V.E.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2018-02
Volume
29
Issue
suppl_2
Pages
ii1-ii9
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2794311213
Cited by
362
References
51
Citations by year
2026: 36 · 2025: 41 · 2024: 41 · 2023: 55 · 2022: 54 · 2021: 56 · 2020: 41 · 2019: 25 · 2018: 13
FWCI
23.30
Type
journal article
Language
en
Open access
Locations
  • Annals of Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Nutrition and Health in Aging
  • Health Sciences › Medicine › Physiology › Body Composition Measurement Techniques
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoma Diagnosis and Treatment
Keywords
sarcopenic obesity, sarcopenia, obesity, muscle atrophy, body composition, cancer treatment complications, survival, dose-limiting toxicity, antineoplastic therapy, body mass index, pharmacokinetics, surgical oncology, medical oncology
MeSH terms
Antineoplastic Agents, Body Composition, Clinical Trials as Topic, Humans, Neoplasms, Obesity, Postoperative Complications, Surgical Procedures, Operative, Body Mass Index, Prevalence, Survival Analysis, Muscle, Skeletal, Neoadjuvant Therapy, Sarcopenia, Chemoradiotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review